Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment of duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs. The company's lead candidate, CAP-1002, an allogeneic cardiac-derived cell therapy, which has completed phase 3 clinical trial for the treatment of patients with late-stage Duchenne muscular dystrophy (DMD). It also focused on developing StealthX, an engineered exosome-based vaccine candidate, under phase 1 clinical study for a range of therapeutic applications, including targeted RNA, protein, and small molecule therapeutics to treat or prevent a variety of diseases. In addition, the company develops CAP-2003, under pre-clinical development for the treatment of trauma related injuries and conditions. It has collaboration and distribution agreement with Nippon Shinyaku Co. Ltd., collaboration agreement with National Institute of Allergy and Infectious Diseases, license agreements with the Johns Hopkins University and Cedars-Sinai Medical Center, as well as cell line license agreement with Life Technologies Corporation. The company was founded in 2005 and is headquartered in San Diego, California. more
Time Frame | CAPR | Sector | S&P500 |
---|---|---|---|
1-Week Return | -10.04% | -3.35% | -2.97% |
1-Month Return | -30.12% | -3.49% | -0.66% |
3-Month Return | 158.52% | -12.6% | 2.71% |
6-Month Return | 171.01% | -6.91% | 7.21% |
1-Year Return | 204.96% | 1.19% | 23.04% |
3-Year Return | 299.38% | -0.21% | 28.43% |
5-Year Return | 1105.61% | 33.09% | 82.88% |
10-Year Return | -65.6% | 93.55% | 184.63% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 1.01M | 310.25K | 244.90K | 2.55M | 25.18M | [{"date":"2019-12-31","value":3.99,"profit":true},{"date":"2020-12-31","value":1.23,"profit":true},{"date":"2021-12-31","value":0.97,"profit":true},{"date":"2022-12-31","value":10.12,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 5.14M | 8.46M | 245.70K | 694.87K | 1.07M | [{"date":"2019-12-31","value":60.8,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":2.91,"profit":true},{"date":"2022-12-31","value":8.22,"profit":true},{"date":"2023-12-31","value":12.64,"profit":true}] |
Gross Profit | (4.14M) | (8.15M) | (799.00) | 1.85M | 24.11M | [{"date":"2019-12-31","value":-17.16,"profit":false},{"date":"2020-12-31","value":-33.79,"profit":false},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":7.69,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | (411.61%) | (2625.87%) | (0.33%) | 72.74% | 95.75% | [{"date":"2019-12-31","value":-429.86,"profit":false},{"date":"2020-12-31","value":-2742.28,"profit":false},{"date":"2021-12-31","value":-0.34,"profit":false},{"date":"2022-12-31","value":75.96,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 8.74M | 14.00M | 21.18M | 32.25M | 48.19M | [{"date":"2019-12-31","value":18.14,"profit":true},{"date":"2020-12-31","value":29.05,"profit":true},{"date":"2021-12-31","value":43.96,"profit":true},{"date":"2022-12-31","value":66.92,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (7.73M) | (13.69M) | (20.94M) | (29.70M) | (24.08M) | [{"date":"2019-12-31","value":-773388800,"profit":false},{"date":"2020-12-31","value":-1368997100,"profit":false},{"date":"2021-12-31","value":-2093844200,"profit":false},{"date":"2022-12-31","value":-2969738300,"profit":false},{"date":"2023-12-31","value":-2407785900,"profit":false}] |
Total Non-Operating Income/Expense | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (7.64M) | (13.66M) | (20.02M) | (29.02M) | (22.29M) | [{"date":"2019-12-31","value":-764181700,"profit":false},{"date":"2020-12-31","value":-1365702800,"profit":false},{"date":"2021-12-31","value":-2002252000,"profit":false},{"date":"2022-12-31","value":-2901953200,"profit":false},{"date":"2023-12-31","value":-2228754200,"profit":false}] |
Income Taxes | (264.03K) | (176.83K) | (613.41K) | (677.85) | (2.00) | [{"date":"2019-12-31","value":-26402700,"profit":false},{"date":"2020-12-31","value":-17683300,"profit":false},{"date":"2021-12-31","value":-61341200,"profit":false},{"date":"2022-12-31","value":-67785,"profit":false},{"date":"2023-12-31","value":-200,"profit":false}] |
Income After Taxes | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (7.64M) | (13.66M) | (20.02M) | (29.02M) | (29.25M) | [{"date":"2019-12-31","value":-764181700,"profit":false},{"date":"2020-12-31","value":-1365702800,"profit":false},{"date":"2021-12-31","value":-2002252000,"profit":false},{"date":"2022-12-31","value":-2901953200,"profit":false},{"date":"2023-12-31","value":-2924636500,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (7.38M) | (13.48M) | (19.41M) | (29.02M) | (22.29M) | [{"date":"2019-12-31","value":-737779000,"profit":false},{"date":"2020-12-31","value":-1348019500,"profit":false},{"date":"2021-12-31","value":-1940910800,"profit":false},{"date":"2022-12-31","value":-2901885415,"profit":false},{"date":"2023-12-31","value":-2228754200,"profit":false}] |
EPS (Diluted) | (2.16) | (0.94) | (0.87) | (1.18) | (0.87) | [{"date":"2019-12-31","value":-216,"profit":false},{"date":"2020-12-31","value":-94,"profit":false},{"date":"2021-12-31","value":-87,"profit":false},{"date":"2022-12-31","value":-118,"profit":false},{"date":"2023-12-31","value":-87,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
CAPR | |
---|---|
Cash Ratio | 4.15 |
Current Ratio | 4.19 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
CAPR | |
---|---|
ROA (LTM) | -44.49% |
ROE (LTM) | -392.69% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
CAPR | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.27 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.73 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
CAPR | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 24.51 |
P/B | 8.35 |
Price/FCF | NM |
EV/R | 20.94 |
EV/Ebitda | NM |
PEG | NM |
Capricor Therapeutics Inc (CAPR) share price today is $12.9
Yes, Indians can buy shares of Capricor Therapeutics Inc (CAPR) on Vested. To buy Capricor Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in CAPR stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Capricor Therapeutics Inc (CAPR) via the Vested app. You can start investing in Capricor Therapeutics Inc (CAPR) with a minimum investment of $1.
You can invest in shares of Capricor Therapeutics Inc (CAPR) via Vested in three simple steps:
The 52-week high price of Capricor Therapeutics Inc (CAPR) is $23.4. The 52-week low price of Capricor Therapeutics Inc (CAPR) is $3.52.
The price-to-earnings (P/E) ratio of Capricor Therapeutics Inc (CAPR) is
The price-to-book (P/B) ratio of Capricor Therapeutics Inc (CAPR) is 8.35
The dividend yield of Capricor Therapeutics Inc (CAPR) is 0.00%
The market capitalization of Capricor Therapeutics Inc (CAPR) is $569.28M
The stock symbol (or ticker) of Capricor Therapeutics Inc is CAPR